VERAXA Biotech Begins Trading on Nasdaq After Completing Business Combination

VERAXA Biotech AG (NASDAQ: VRXA) announced the successful closing of its business combination with Voyager Acquisition Corp. (NASDAQ: VACH), resulting in the formation of a new entity that began trading on the Nasdaq Capital Market on an undisclosed date. The company, which is developing a pipeline of bispecific T-cell engagers and antibody-drug conjugates, will trade under the ticker symbol VRXA, with warrants trading under VRXAW.

The business combination marks a significant milestone for VERAXA, which is focused on advancing its proprietary BiTAC platform. This platform is designed to selectively target cancer cells while sparing healthy tissue, potentially offering a more precise approach to oncology treatment. The company’s lead candidate, a BiTAC-TCE, recently presented preclinical data at the AACR Annual Meeting 2026, demonstrating favorable efficacy and safety characteristics.

To support its clinical development plans, VERAXA has secured financing through a $27.5 million senior secured note and a securities purchase agreement of up to $50 million. These proceeds are expected to advance the BiTAC-TCE and BiTAC-ADC programs toward clinical development. The company’s technology is based on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution.

Voyager Acquisition Corp., the special purpose acquisition company that merged with VERAXA, was established with the mission to revolutionize the healthcare sector through strategic combinations. Its team of experienced executives brings expertise in investing, operations, and medical innovation, supported by a vast network of connections.

The listing on Nasdaq provides VERAXA with access to public capital markets, which could accelerate its research and development efforts. The company’s focus on next-generation antibody-based therapeutics, including bispecific T cell engagers and bispecific ADCs, positions it in a competitive landscape where precision medicine is increasingly valued.

For more information, visit the company’s newsroom at http://ibn.fm/VRXA and the company’s website at www.veraxa.com.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is VERAXA Biotech Begins Trading on Nasdaq After Completing Business Combination.

The post VERAXA Biotech Begins Trading on Nasdaq After Completing Business Combination appeared first on citybuzz.